AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19120050 — intervention group
Group type: EXPERIMENTAL
Intervention: Video (9.5-minute animated and live-action video)
Number of subjects: 574
Study 19120050 — intervention group
Group type: COMPARATOR
Intervention: In-person information session
Number of subjects: 574
Study 17692742 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan and spironolactone (combination group)
Number of subjects: 51
Study 17692742 — intervention group
Group type: COMPARATOR
Intervention: Candesartan and placebo (control group)
Number of subjects: 51
Study 15064598 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-body training (TP, N = 18, 3-8 RM training range)
Number of subjects: 85
Study 15064598 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-body training (TH, N = 21, 8-12 RM training range)
Number of subjects: 85
Study 15064598 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body training (UP, N = 21, 3-8 RM training range)
Number of subjects: 85
Study 15064598 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body training (UH, N = 19, 8-12 RM training range)
Number of subjects: 85
Study 15064598 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, N = 6)
Number of subjects: 85
Study 11526203 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria DNA vaccine administered by needle i.m. or needleless jet injection
Number of subjects: 14
Study 9817534 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatments for multiple sclerosis
Number of subjects: 0
Study 7544030 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (up to 250 mg/m2) followed by Carboplatin (up to 400 mg/m2)
Number of subjects: 62
Study 7544030 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (300 mg/m2) with Paclitaxel (200 mg/m2)
Number of subjects: 62
Study 7544030 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (250 mg/m2) with Carboplatin (350 mg/m2)
Number of subjects: 62
Study 7544030 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (above 200 mg/m2)
Number of subjects: 62
Study 7544030 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and Carboplatin (both sequences)
Number of subjects: 62
Study 2652281 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month therapy with a fixed combination of 120 mg rifampicin, 50 mg isoniazid, and 300 mg pyrazinamide (Rifater)
Number of subjects: 93
Study 2652281 — intervention group
Group type: COMPARATOR
Intervention: Present Swiss standard therapy (Daily rifampicin, isoniazid, and ethambutol for 2 months followed by rifampicin and isoniazid for 7 months)
Number of subjects: 93
Study 788758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol administered once daily
Number of subjects: 0
Study 788758 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol administered once daily
Number of subjects: 0
Study 788758 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blocking drugs (general)
Number of subjects: 0
Study 30863471 — intervention group
Group type: EXPERIMENTAL
Intervention: USG bilateral subcostal TAP block with 0.3 ml/kg bupivacaine
Number of subjects: 120
Study 30863471 — intervention group
Group type: COMPARATOR
Intervention: USG bilateral QL block with 0.3 ml/kg bupivacaine
Number of subjects: 120
Study 30863471 — intervention group
Group type: EXPERIMENTAL
Intervention: USG bilateral subcostal TAP block
Number of subjects: 120
Study 30863471 — intervention group
Group type: COMPARATOR
Intervention: USG bilateral QL block
Number of subjects: 120
Study 28025574 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Physical Activity Intervention (PAI)
Number of subjects: 75
Study 28025574 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 75
Study 26228178 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% w/v CPP‐ACP paste
Number of subjects: 103
Study 26228178 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 103
Study 23531425 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look endoscopy (SLE)
Number of subjects: 182
Study 23531425 — intervention group
Group type: COMPARATOR
Intervention: No second-look endoscopy (no-SLE)
Number of subjects: 182
Study 23531425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SLE and no-SLE)
Number of subjects: 182
Study 21390582 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage of Astragalus granule (7.5 g)
Number of subjects: 90
Study 21390582 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dosage of Astragalus granule (4.5 g)
Number of subjects: 90
Study 21390582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage of Astragalus granule (2.25 g)
Number of subjects: 90
Study 21390582 — intervention group
Group type: COMPARATOR
Intervention: Perindopril (4 mg)
Number of subjects: 90
Study 19721214 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hip abduction test (examiner scored)
Number of subjects: 43
Study 19721214 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hip abduction test (self-rated)
Number of subjects: 43
Study 19721214 — intervention group
Group type: COMPARATOR
Intervention: Prolonged standing protocol
Number of subjects: 43
Study 17443000 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2-based immunotherapy
Number of subjects: 363
Study 15013613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide
Number of subjects: 60
Study 15013613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Number of subjects: 60
Study 15013613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone
Number of subjects: 60
Study 15013613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11440296 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal and telephone reminders during the first 2 months of pravastatin treatment
Number of subjects: 12800
Study 11440296 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12800
Study 9754889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg in D5W
Number of subjects: 6
Study 9754889 — intervention group
Group type: COMPARATOR
Intervention: D5W alone
Number of subjects: 6
Study 8058228 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg twice daily) for two 2-day courses, first at 24 weeks' gestation and second at 29 weeks if G vaginalis was present.
Number of subjects: 196
Study 8058228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 8058228 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (after second course)
Number of subjects: 196
Study 2702513 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of nasally applied budesonide twice daily
Number of subjects: 98
Study 2702513 — intervention group
Group type: COMPARATOR
Intervention: 250 micrograms of orally administered budesonide twice daily
Number of subjects: 98
Study 2702513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 769572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine 75 mg and sulfadoxine 1,500 mg
Number of subjects: 0
Study 769572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine 50 mg and diformyldapsone 800 mg
Number of subjects: 0
Study 769572 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine alone
Number of subjects: 0
Study 769572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadoxine
Number of subjects: 0
Study 769572 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine-diformyldapsone
Number of subjects: 0
Study 31461400 — intervention group
Group type: EXPERIMENTAL
Intervention: Active continuous diffusion of oxygen (CDO)
Number of subjects: 146
Study 31461400 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 146
Study 31461400 — intervention group
Group type: EXPERIMENTAL
Intervention: Active continuous diffusion of oxygen (CDO) with frequent debridement
Number of subjects: 146
Study 31461400 — intervention group
Group type: COMPARATOR
Intervention: Placebo device with frequent debridement
Number of subjects: 146
Study 26941340 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR 70-130/min biventricular pacing
Number of subjects: 60
Study 26941340 — intervention group
Group type: COMPARATOR
Intervention: VVI 70/min biventricular pacing
Number of subjects: 60
Study 26073497 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (3 hours)
Number of subjects: 98
Study 23174256 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate
Number of subjects: 280
Study 23174256 — intervention group
Group type: COMPARATOR
Intervention: Plasmakinetic resection of the prostate
Number of subjects: 280
Study 16847815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide plus tamoxifen
Number of subjects: 0
Study 16847815 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide
Number of subjects: 0
Study 16847815 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide plus anastrozole
Number of subjects: 0
Study 12900688 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX/D
Number of subjects: 12
Study 12900688 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX/DDelta
Number of subjects: 12
Study 12900688 — intervention group
Group type: COMPARATOR
Intervention: FU system
Number of subjects: 12
Study 10481867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intron-A (interferon-alpha 2b) at standard doses (5 IU/m2/day)
Number of subjects: 42
Study 10481867 — intervention group
Group type: COMPARATOR
Intervention: Low-dose interferon-alpha-2b (reaferon and intron-A, 1-3 IU/m2/day) in combination with chemotherapy
Number of subjects: 42
Study 9086958 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive intervention to reduce postnatal depression
Number of subjects: 249
Study 9086958 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 249
Study 9086958 — intervention group
Group type: EXPERIMENTAL
Intervention: MASQ vulnerable group
Number of subjects: 249
Study 9086958 — intervention group
Group type: COMPARATOR
Intervention: MASQ less vulnerable group
Number of subjects: 249
Study 1713091 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 26
Study 1713091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6880922 — intervention group
Group type: EXPERIMENTAL
Intervention: Television with drinking depicted
Number of subjects: 0
Study 6880922 — intervention group
Group type: EXPERIMENTAL
Intervention: Television without drinking
Number of subjects: 0
Study 6880922 — intervention group
Group type: COMPARATOR
Intervention: No television control condition
Number of subjects: 0
Study 31796528 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma α‐linolenic acid (ALA) in men
Number of subjects: 275
Study 31796528 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma arachidonic acid in women
Number of subjects: 275
Study 31796528 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma docosahexaenoic acid (DHA) in men and women combined
Number of subjects: 275
Study 30685759 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hematological parameters (specifically platelet count)
Number of subjects: 0
Study 30685759 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental volume
Number of subjects: 0
Study 30685759 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical arterial lumen cross-sectional area
Number of subjects: 0
Study 30685759 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hematological parameters
Number of subjects: 0
Study 28291023 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz NMES protocol
Number of subjects: 10
Study 28291023 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Hz NMES protocol
Number of subjects: 10
Study 28291023 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz NMES protocol
Number of subjects: 10
Study 25150812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 24
Study 25150812 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (Control)
Number of subjects: 24
Study 23448393 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery by MDLAP
Number of subjects: 12
Study 23448393 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 12
Study 21314329 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin administration
Number of subjects: 0
Study 19824094 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine administration
Number of subjects: 0
Study 19824094 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 infusion
Number of subjects: 0
Study 19824094 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular fluid volume expansion
Number of subjects: 0
Study 19824094 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration/hemodialysis
Number of subjects: 0
Study 19824094 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of radiocontrast media
Number of subjects: 0
Study 16414263 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait Walker (DeRoyal Industries, Inc.)
Number of subjects: 11
Study 16414263 — intervention group
Group type: EXPERIMENTAL
Intervention: Equalizer (Royce Medical Co.)
Number of subjects: 11
Study 16414263 — intervention group
Group type: COMPARATOR
Intervention: Laboratory shoes (Noveto, Adidas)
Number of subjects: 11
Study 14604059 — intervention group
Group type: EXPERIMENTAL
Intervention: Centella asiatica and Punica granatum extracts (medicated chips)
Number of subjects: 20
Study 14604059 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated chips (placebo)
Number of subjects: 20
Study 14604059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and control groups
Number of subjects: 20
Study 10783014 — intervention group
Group type: EXPERIMENTAL
Intervention: aP vaccine
Number of subjects: 1207
Study 10783014 — intervention group
Group type: COMPARATOR
Intervention: TdaP‐IPV vaccine
Number of subjects: 1207
Study 10783014 — intervention group
Group type: COMPARATOR
Intervention: Td‐IPV
Number of subjects: 1207
Study 10783014 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of acellular pertussis vaccine
Number of subjects: 1207
Study 8854782 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial infusion (AI) chemotherapy
Number of subjects: 41
Study 8854782 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy (ST)
Number of subjects: 41
Study 1616115 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (0.075 mg/kg)
Number of subjects: 100
Study 1616115 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.15 mg/kg)
Number of subjects: 100
Study 1616115 — intervention group
Group type: COMPARATOR
Intervention: NaCl (0.1 ml/kg)
Number of subjects: 100
Study 6380362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 219
Study 6380362 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 219
Study 6380362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 219
Study 30368898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programme consisting of four group sessions, 84 SMS or voice messages, and review phone calls over the first year; additional individual sessions for those needing intensification.
Number of subjects: 1414
Study 30368898 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1414
Study 29767728 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg andecaliximab every 2 weeks (Q2W)
Number of subjects: 0
Study 29767728 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg andecaliximab weekly (QW)
Number of subjects: 0
Study 29767728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29767728 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg andecaliximab Q2W and QW
Number of subjects: 0
Study 29767728 — intervention group
Group type: COMPARATOR
Intervention: 150 mg andecaliximab and placebo
Number of subjects: 0
Study 27524768 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 0
Study 27524768 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 25252254 — intervention group
Group type: EXPERIMENTAL
Intervention: Close-up White Now
Number of subjects: 60
Study 25252254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B 3D White
Number of subjects: 60
Study 25252254 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Luminous White
Number of subjects: 60
Study 25252254 — intervention group
Group type: COMPARATOR
Intervention: Colgate Total 12
Number of subjects: 60
Study 22363361 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam/Ketamine
Number of subjects: 0
Study 22363361 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam/Promethazine
Number of subjects: 0
Study 20164411 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily reinforcement of speed (DRS) after a single, daily 10-m walk
Number of subjects: 179
Study 20164411 — intervention group
Group type: COMPARATOR
Intervention: No reinforcement of speed (NRS) after the walk
Number of subjects: 179
Study 20164411 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily reinforcement of speed (DRS)
Number of subjects: 179
Study 20164411 — intervention group
Group type: COMPARATOR
Intervention: No reinforcement of speed (NRS)
Number of subjects: 179
Study 17379123 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine 0.5 mg/kg in 2 mL saline before surgery, followed by continuous IV infusion of ketamine at 6 micro/(kg/min)
Number of subjects: 90
Study 17379123 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (10 mL/h) until bleeding control, with 0.8 mg/kg ketamine during bleeding control in 2 mL saline
Number of subjects: 90
Study 17379123 — intervention group
Group type: COMPARATOR
Intervention: Saline only
Number of subjects: 90
Study 15747897 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive subantimicrobial dose doxycycline (SDD; 20 mg doxycycline twice daily)
Number of subjects: 24
Study 15747897 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) + placebo
Number of subjects: 24
Study 11874994 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI + 1 day of H2RA (ranitidine 300 mg)
Number of subjects: 43
Study 11874994 — intervention group
Group type: COMPARATOR
Intervention: PPI twice daily alone
Number of subjects: 43
Study 11874994 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI twice daily + H2RA after 1 week
Number of subjects: 43
Study 10518812 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Number of subjects: 0
Study 10518812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 0
Study 10518812 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study 10518812 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 0
Study 10518812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 7616418 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.025 microgram/kg/min)
Number of subjects: 12
Study 7616418 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.1 microgram/kg/min)
Number of subjects: 12
Study 7616418 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (0.5 microgram/kg/min)
Number of subjects: 12
Study 7616418 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (6 micrograms/kg)
Number of subjects: 12
Study 7616418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (instead of naloxone)
Number of subjects: 12
Study 2264621 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein (600 units orally per day) for 3 months
Number of subjects: 65
Study 2264621 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 65
Study 538213 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (N = 30)
Number of subjects: 47
Study 538213 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 17)
Number of subjects: 47
Study 30142133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ujjayi breathing technique
Number of subjects: 32
Study 30142133 — intervention group
Group type: EXPERIMENTAL
Intervention: Bhastrika breathing technique
Number of subjects: 32
Study 30142133 — intervention group
Group type: EXPERIMENTAL
Intervention: Kapalabhati breathing technique
Number of subjects: 32
Study 30142133 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing (control)
Number of subjects: 32
Study 30142133 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic power measured at 60, 180, and 300°·s
Number of subjects: 32
Study 30653531 — intervention group
Group type: EXPERIMENTAL
Intervention: Health‐literate action plan (guided implementation intention)
Number of subjects: 440
Study 30653531 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard action plan (self‐guided implementation intention)
Number of subjects: 440
Study 30653531 — intervention group
Group type: COMPARATOR
Intervention: Education (healthy snacking fact‐sheet)
Number of subjects: 440
Study 28122105 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg orally, once daily) for 10 days
Number of subjects: 39
Study 28122105 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 39
Study 28122105 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine with amoxicillin‐clavulanic acid, pseudoephedrine, and intranasal normal saline
Number of subjects: 39
Study 24256097 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 11
Study 22889929 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-supported gait training with the Lokomat
Number of subjects: 25
Study 22889929 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS)
Number of subjects: 25
Study 22889929 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy with visual feedback components (PT-vf)
Number of subjects: 25
Study 21056671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MPA)
Number of subjects: 34
Study 21056671 — intervention group
Group type: COMPARATOR
Intervention: NONMEM
Number of subjects: 34
Study 21056671 — intervention group
Group type: EXPERIMENTAL
Intervention: NPAG
Number of subjects: 34